These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23319575)

  • 21. Outcomes in Adult Acute Promyelocytic Leukemia: A Decade Experience.
    Yedla RP; Bala SC; Pydi VR; Kuruva SP; Chennamaneni R; Konatam ML; Paul TR; Gundeti S
    Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):e158-e164. PubMed ID: 31992504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia.
    Hecht A; Nowak D; Nowak V; Hanfstein B; Faldum A; Büchner T; Spiekermann K; Sauerland C; Lengfelder E; Hofmann WK; Nolte F
    Ann Hematol; 2013 Apr; 92(4):443-9. PubMed ID: 23250622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis.
    Li X; Wang C; Chen G; Ji B; Xu Y
    Hematology; 2017 Sep; 22(8):450-459. PubMed ID: 28480800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia.
    Candoni A; Damiani D; Michelutti A; Masolini P; Michieli M; Michelutti T; Geromin A; Fanin R
    Eur J Haematol; 2003 Jul; 71(1):1-8. PubMed ID: 12801292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.
    Lengfelder E; Görlich D; Nowak D; Spiekermann K; Haferlach C; Krug U; Kreuzer KA; Braess J; Schliemann C; Lindemann HW; Horst HA; Schiel X; Flasshove M; Hecht A; Schnittger S; Schneider S; Wörmann B; Hofmann WK; Berdel WE; Bormann E; Sauerland C; Büchner T; Hiddemann W;
    Eur J Haematol; 2018 Feb; 100(2):154-162. PubMed ID: 29114972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ider(17)(q10)t(15;17) associated with relapse and poor prognosis in a pediatric patient with acute promyelocytic leukemia.
    Kim MJ; Yoon HS; Cho SY; Lee HJ; Suh JT; Lee J; Yoon HJ; Lee WI; Park TS
    Cancer Genet Cytogenet; 2010 Sep; 201(2):116-21. PubMed ID: 20682396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of international collaboration on the prognosis of childhood acute promyelocytic leukemia in Iraq.
    Testi AM; Al-Hadad SA; Al-Jadiry MF; Moleti ML; Mandelli F; Foà R
    Haematologica; 2006 Apr; 91(4):509-12. PubMed ID: 16533724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
    Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
    Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The effects of different post-remission treatment on long-term survival of acute promyelocytic leukemia].
    Li X; Zhao YZ; Li ZJ; Yang RC; Han MZ; Qiu LG
    Zhonghua Nei Ke Za Zhi; 2006 Sep; 45(9):741-3. PubMed ID: 17166449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addressing the room for improvement in management of acute promyelocytic leukemia.
    Nørgaard JM; Friis LS; Kristensen JS; Severinsen MT; Mølle I; Marcher CW; Møller P; Schoellkopf C; Nielsen OJ; Preiss BS; Andersen MK; Kjeldsen E; Medeiros BC; Østgård LSG;
    Eur J Haematol; 2019 Jun; 102(6):479-485. PubMed ID: 30887583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children's Hospital APL 2005 protocol (BCH-APL 2005).
    Zhang Y; Wang L; Zhang R; Qi P; Xie J; Shi H; Lin W; Wu Y; Yu J; Fan J; Feng G; Zheng H; Wu M
    Pediatr Hematol Oncol; 2019 Oct; 36(7):399-409. PubMed ID: 31530209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.
    Koury LCA; Kim HT; Undurraga MS; Navarro-Cabrera JR; Salinas V; Muxi P; Melo RAM; Glória AB; Pagnano K; Nunes EC; Bittencourt RI; Rojas N; Quintana S; Ayala-Lugo A; Oliver AC; Figueiredo-Pontes L; Traina F; Moreira F; Fagundes EM; Duarte BKL; Mora-Alferez AP; Ortiz P; Untama J; Tallman M; Ribeiro R; Ganser A; Dillon R; Valk PJM; Sanz M; Löwenberg B; Berliner N; Rego EM
    Blood; 2024 Sep; 144(12):1257-1270. PubMed ID: 38805638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience.
    Head DR; Kopecky KJ; Willman C; Appelbaum FR
    Leukemia; 1994; 8 Suppl 2():S38-41. PubMed ID: 7815835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission.
    Muchtar E; Vidal L; Ram R; Gafter-Gvili A; Shpilberg O; Raanani P
    Cochrane Database Syst Rev; 2013 Mar; (3):CD009594. PubMed ID: 23543579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival and treatment response in adults with acute promyelocytic leukemia treated with a modified International Consortium on Acute Promyelocytic Leukemia protocol.
    Crespo-Solis E; Contreras-Cisneros J; Demichelis-Gómez R; Rosas-López A; Vera-Zertuche JM; Aguayo A; López-Karpovitch X
    Rev Bras Hematol Hemoter; 2016; 38(4):285-290. PubMed ID: 27863754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
    Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
    Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
    Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
    J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country.
    Lins MM; Mello MJG; Ribeiro RC; De Camargo B; de Fátima Pessoa Militão de Albuquerque M; Thuler LCS
    Ann Hematol; 2019 Jun; 98(6):1403-1411. PubMed ID: 30915498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre.
    Karim F; Shaikh U; Adil SN; Khurshid M
    Singapore Med J; 2014 Aug; 55(8):443-7. PubMed ID: 25189308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.